AN2 Therapeutics Announces Q3 2025 Financial Results and Key Corporate & Scientific Updates
AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business and Scientific Updates AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company dedicated to discovering and developing novel small-molecule therapeutics…
Kezar Life Sciences Announces Q3 2025 Financial Results
Kezar Life Sciences Provides Third Quarter 2025 Financial and Corporate Update Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics targeting immune-mediated diseases, announced…
Deciphera to Showcase New Clinical Data at the 2025 CTOS Annual Meeting
Deciphera to Present Comprehensive Pipeline Data at the 2025 Connective Tissue Oncology Society (CTOS) Annual Meeting Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) and…
Dyno Therapeutics, Trisk Bio Form Strategic Manufacturing Partnership
Dyno Therapeutics and Trisk Bio Forge Strategic Manufacturing Alliance to Advance Genetic Agency through Expanded Frontiers Program Dyno Therapeutics, Inc., a genetic technologies company leveraging artificial intelligence (AI) to revolutionize…
Ionis Pharmaceuticals Announces New Convertible Offering for 2026 Note Refinancing
Ionis Pharmaceuticals Announces $700 Million Convertible Senior Notes Offering to Refinance 2026 Debt and Strengthen Long-Term Financial Flexibility Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), a leading biopharmaceutical company advancing RNA-targeted therapeutics,…
enGene’s Detalimogene Shows Improved Six-Month Complete Response Rate of 62%
enGene Reports Updated LEGEND Phase 2 Data Showing 62% Complete Response Rate at Six Months for Detalimogene Voraplasmid in BCG-Unresponsive NMIBC enGene Holdings Inc. (Nasdaq: ENGN) (“enGene” or the “Company”),…
FDA Approves Promega OncoMate MSI Dx as Companion Test for KEYTRUDA + LENVIMA in Endometrial Cancer
FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® Plus LENVIMA® in Advanced Endometrial Carcinoma The U.S. Food and Drug Administration (FDA) has officially approved the…
Samsung Epis Holdings Launches Epis NexLab to Drive Next-Gen Biotech Innovation
Samsung Epis Holdings Launches Epis NexLab to Pioneer Next-Generation Biotech Platforms and Drive Global Innovation Samsung Epis Holdings Co., Ltd. has officially announced the establishment of Epis NexLab Co., Ltd.,…
Arcturus Therapeutics Reports Third Quarter 2025 Financial Results and Pipeline Updates
Arcturus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Corporate Updates Arcturus Therapeutics Holdings Inc. (“Arcturus” or the “Company”) (Nasdaq: ARCT), a commercial-stage messenger RNA (mRNA) medicines company…
PharmaEssentia USA Appoints Dr. Barry Flannelly as Independent Director
PharmaEssentia USA Appoints Dr. Barry Flannelly as Independent Director, Strengthening Leadership Amid Expanding Global Ambitions PharmaEssentia USA Corporation, a wholly owned subsidiary of PharmaEssentia Corporation (TWSE: 6446), today announced the…
TFDA Approves Orphan Drug Designation for Tinostamustine in Malignant Glioma
FDA Grants Orphan Drug Designation to Tinostamustine for the Treatment of Malignant Glioma Purdue Pharma L.P. (“Purdue”) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan…
CuraSen Reports Positive Phase 1 Data for CuraAX (CST-3056) at 2025 AAS Symposium
CuraSen Therapeutics Presents Positive Phase 1 Data Demonstrating Safety, Pharmacokinetics, and Pharmacodynamics of CuraAX (CST-3056) at the 2025 American Autonomic Society International Symposium CuraSen Therapeutics, Inc., a privately held biopharmaceutical…